Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024

Thomas W. LeBlanc, MD, MA, discusses how treatment regimens for low-risk myelodysplastic syndromes (LR-MDS) significantly impact health-related quality of life (HRQOL), with data from the COMMANDS study (Oliva et al, ASH 2024, Abstract 3216) highlighting the correlation between HRQOL and clinical end points, and explore how incorporating HRQOL data into clinical decision-making can guide more patient-centered treatment choices in community settings.

EP: 1.An Overview of the Treatment Landscape for Anemia Management in LR-MDS

EP: 2.Updates From COMMANDS at ASH 2024

EP: 3.The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS

EP: 4.Considerations for Treatment Sequencing in LR-MDS

Now Viewing

EP: 5.Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024

Video content above is prompted by the following:

How do treatment regimens impact HRQOL in LR-MDS?

• Please review and discuss HRQOL from COMMANDS: Oliva et al, ASH 2024, Abstract 3216.
• How do HRQOL data correlate with clinical end points?
• How can HRQOL data impact treatment choices in the community?
  

Recent Videos